Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lisuride
Drug ID BADD_D01301
Description An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Indications and Usage For the management of Parkinson's Disease
Marketing Status approved; investigational
ATC Code G02CB02; N02CA07
DrugBank ID DB00589
KEGG ID D08132
MeSH ID D008090
PubChem ID 28864
TTD Drug ID D0X7KB
NDC Product Code Not Available
UNII E0QN3D755O
Synonyms Lisuride | Lysurid | Methylergol Carbamide | Carbamide, Methylergol | Arolac | Cuvalit | Dopergine | Dopergin | Revanil | Lisuride, (8alpha)-(+-)-Isomer | Lysenyl | Lisuride Maleate | Maleate, Lisuride | Lysuride Hydrogen Maleate | Hydrogen Maleate, Lysuride | Lisuride Maleate (1:1) | Lisuride Maleate, (8beta)-Isomer | Lisuride Mesylate | Mesylate, Lisuride | Lisuride Phosphate (1:1) | Lisuride Hydrochloride | Hydrochloride, Lisuride
Chemical Information
Molecular Formula C20H26N4O
CAS Registry Number 18016-80-3
SMILES CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Palpitations02.11.04.012--
Pericardial effusion02.06.01.002--
Pericarditis02.06.02.001--
Peripheral coldness23.06.04.008; 24.04.03.006; 08.01.09.010--Not Available
Pleural effusion22.05.02.002--
Pleural fibrosis22.05.03.003--Not Available
Pleurisy22.05.01.001--Not Available
Pulmonary fibrosis22.01.02.006--
Retroperitoneal fibrosis20.06.01.006; 10.02.01.026; 07.07.03.003--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.015--
Tachycardia02.03.02.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Sudden onset of sleep17.15.04.003--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.11.01.003--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Mental disorder due to a general medical condition19.07.03.005--Not Available
Cardiac valve disease02.07.02.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Hypersexuality19.08.03.005--Not Available
Regurgitation07.01.07.004--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages